These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 19882901)
21. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice. Jazayeri M; Soleimanjahi H; Fotouhi F; Pakravan N Comp Immunol Microbiol Infect Dis; 2009 Sep; 32(5):453-61. PubMed ID: 18571235 [TBL] [Abstract][Full Text] [Related]
22. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Hu K; Dou J; Yu F; He X; Yuan X; Wang Y; Liu C; Gu N Vaccine; 2011 Feb; 29(7):1455-62. PubMed ID: 21185849 [TBL] [Abstract][Full Text] [Related]
23. HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2. Mori I; Liu B; Goshima F; Ito H; Koide N; Yoshida T; Yokochi T; Kimura Y; Nishiyama Y Microbes Infect; 2005 Dec; 7(15):1492-500. PubMed ID: 16054416 [TBL] [Abstract][Full Text] [Related]
24. Herpes simplex: insights on pathogenesis and possible vaccines. Koelle DM; Corey L Annu Rev Med; 2008; 59():381-95. PubMed ID: 18186706 [TBL] [Abstract][Full Text] [Related]
26. The potential of currently unavailable herpes virus vaccines. Rajčáni J; Bánáti F; Szenthe K; Szathmary S Expert Rev Vaccines; 2018 Mar; 17(3):239-248. PubMed ID: 29313728 [TBL] [Abstract][Full Text] [Related]
27. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting. Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350 [TBL] [Abstract][Full Text] [Related]
28. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge. Jamali A; Roostaee MH; Soleimanjahi H; Ghaderi Pakdel F; Bamdad T Comp Immunol Microbiol Infect Dis; 2007 Mar; 30(2):71-80. PubMed ID: 17126902 [TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834 [TBL] [Abstract][Full Text] [Related]
30. Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity. Cortesi R; Argnani R; Esposito E; Dalpiaz A; Scatturin A; Bortolotti F; Lufino M; Guerrini R; Cavicchioni G; Incorvaia C; Menegatti E; Manservigi R Int J Pharm; 2006 Jul; 317(1):90-100. PubMed ID: 16600535 [TBL] [Abstract][Full Text] [Related]
31. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs. Simms JR; Heath AW; Jennings R J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560 [TBL] [Abstract][Full Text] [Related]
32. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Dasgupta G; Chentoufi AA; Nesburn AB; Wechsler SL; BenMohamed L Expert Rev Vaccines; 2009 Aug; 8(8):1023-35. PubMed ID: 19627185 [TBL] [Abstract][Full Text] [Related]
33. A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes. Slomka MJ; Emery L; Munday PE; Moulsdale M; Brown DW J Med Virol; 1998 Jun; 55(2):177-83. PubMed ID: 9598940 [TBL] [Abstract][Full Text] [Related]
36. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Da Costa XJ; Bourne N; Stanberry LR; Knipe DM Virology; 1997 May; 232(1):1-12. PubMed ID: 9185583 [TBL] [Abstract][Full Text] [Related]
37. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Bettahi I; Zhang X; Afifi RE; BenMohamed L Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765 [TBL] [Abstract][Full Text] [Related]
38. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. Augustinova H; Hoeller D; Yao F J Virol; 2004 Jun; 78(11):5756-65. PubMed ID: 15140973 [TBL] [Abstract][Full Text] [Related]